Lv1
50 积分 2023-12-18 加入
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
2个月前
已完结
The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies
2个月前
已完结
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
2个月前
已完结
Elranatamab: First Approval
2个月前
已完结
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
2个月前
已完结
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
3个月前
已完结
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial
4个月前
已完结
P-334 Ixazomib-Based Maintenance Therapy in Multiple Myeloma Patients Eligible and Ineligible for Transplantation: A Real-World Study (INFINITE Study)
6个月前
已完结
P-334 Ixazomib-Based Maintenance Therapy in Multiple Myeloma Patients Eligible and Ineligible for Transplantation: A Real-World Study (INFINITE Study)
6个月前
已关闭
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
6个月前
已完结
皖公网安备34019202002308
